New Targeted Therapies for Metastatic Non–Small Cell Lung Cancer
Search for other papers by Gregory J. Riely in
Current site
Google Scholar
PubMed
Biomarker testing is essential for the management of patients with metastatic non–small cell lung cancer (NSCLC) to identify specific actionable mutations and guide treatment decisions in EGFR-mutant disease and for the potential benefit of combining tyrosine kinase inhibitors with chemotherapy to improve progression-free survival. For instance, for patients with EGFR exon 20 insertions, the role of amivantamab, an EGFR-MET–bispecific antibody, is being explored in the first-line and second-line settings, in addition to the use of ROS1 inhibitors, such as repotrectinib, in the treatment of ROS1-rearranged NSCLC. For patients with BRAF V600E mutations, combining BRAF and MEK inhibitors, such as dabrafenib and trametinib or encorafenib and binimetinib, has demonstrated efficacy. The potential of the antibody–drug conjugate fam-trastuzumab deruxtecan-nxki in treating HER2-mutant NSCLC is under investigation. Finally, for patients with KRAS G12C mutations, sotorasib and adagrasib have been tested as second-line therapies, with ongoing trials evaluating their use in the first-line setting.
Disclosures: Dr. Riely has disclosed receiving grant/research support from Amgen Inc., Eli Lilly and Company, Merck & Co., Inc., Mirati Therapeutics, Inc., Novartis Pharmaceuticals Corporation, Pfizer Inc., Roche Laboratories, Inc., and Takeda Pharmaceuticals North America, Inc.
© 2019-2024 National Comprehensive Cancer Network